Led by researchers at MD Anderson Cancer Center, the study demonstrated an overall objective response rate of 25% (n=4) among patients with various solid tumor types BVD is advancing CNV-NT, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results